Record global in-market sales of Copaxone of $2.8 billion in the year ended 2009, up 25% in the fourth quarter and for the full year compared to 2008. Copaxone® continues to be the leading MS therapy in the U.S. and globally.
Teva Reports Record Full Year 2009 And Fourth Quarter Results
Market Data 
Markets 
AI
